Fortrea (FTRE) Competitors

Fortrea logo
$19.59 -0.20 (-1.01%)
Closing price 04:00 PM Eastern
Extended Trading
$19.59 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

FTRE vs. TWST, TXG, CAI, ADPT, and SHC

Should you buy Fortrea stock or one of its competitors? Fortrea's main competitors and comparable companies include Twist Bioscience (TWST), 10x Genomics (TXG), Caris Life Sciences (CAI), Adaptive Biotechnologies (ADPT), and Sotera Health (SHC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Fortrea compare to Twist Bioscience?

Fortrea (NASDAQ:FTRE) and Twist Bioscience (NASDAQ:TWST) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Fortrea currently has a consensus price target of $24.23, indicating a potential upside of 20.47%. Twist Bioscience has a consensus price target of $133.92, indicating a potential upside of 26.65%. Given Twist Bioscience's higher possible upside, analysts clearly believe Twist Bioscience is more favorable than Fortrea.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortrea
2 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.46
Twist Bioscience
2 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.42

Twist Bioscience has lower revenue, but higher earnings than Fortrea. Twist Bioscience is trading at a lower price-to-earnings ratio than Fortrea, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortrea$2.72B0.71-$986.20M-$0.73N/A
Twist Bioscience$459.43M14.43-$77.67M-$2.09N/A

Fortrea has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market.

Fortrea has a net margin of -2.58% compared to Twist Bioscience's net margin of -28.34%. Fortrea's return on equity of 13.98% beat Twist Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Fortrea-2.58% 13.98% 2.76%
Twist Bioscience -28.34%-27.53%-18.80%

In the previous week, Twist Bioscience had 27 more articles in the media than Fortrea. MarketBeat recorded 37 mentions for Twist Bioscience and 10 mentions for Fortrea. Fortrea's average media sentiment score of 0.58 beat Twist Bioscience's score of 0.35 indicating that Fortrea is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fortrea
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Twist Bioscience
8 Very Positive mention(s)
4 Positive mention(s)
13 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Fortrea beats Twist Bioscience on 9 of the 15 factors compared between the two stocks.

How does Fortrea compare to 10x Genomics?

10x Genomics (NASDAQ:TXG) and Fortrea (NASDAQ:FTRE) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

Fortrea has a net margin of -2.58% compared to 10x Genomics' net margin of -10.84%. Fortrea's return on equity of 13.98% beat 10x Genomics' return on equity.

Company Net Margins Return on Equity Return on Assets
10x Genomics-10.84% -8.19% -6.46%
Fortrea -2.58%13.98%2.76%

10x Genomics currently has a consensus price target of $68.40, indicating a potential upside of 25.89%. Fortrea has a consensus price target of $24.23, indicating a potential upside of 20.47%. Given 10x Genomics' higher probable upside, analysts clearly believe 10x Genomics is more favorable than Fortrea.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
10x Genomics
1 Sell rating(s)
12 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.22
Fortrea
2 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.46

In the previous week, 10x Genomics had 4 more articles in the media than Fortrea. MarketBeat recorded 14 mentions for 10x Genomics and 10 mentions for Fortrea. Fortrea's average media sentiment score of 0.58 beat 10x Genomics' score of 0.19 indicating that Fortrea is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
10x Genomics
3 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fortrea
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

10x Genomics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the broader market. Comparatively, Fortrea has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market.

84.7% of 10x Genomics shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by company insiders. Comparatively, 0.7% of Fortrea shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

10x Genomics has higher earnings, but lower revenue than Fortrea. 10x Genomics is trading at a lower price-to-earnings ratio than Fortrea, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
10x Genomics$642.82M11.01-$43.54M-$0.52N/A
Fortrea$2.72B0.71-$986.20M-$0.73N/A

Summary

Fortrea beats 10x Genomics on 9 of the 17 factors compared between the two stocks.

How does Fortrea compare to Caris Life Sciences?

Fortrea (NASDAQ:FTRE) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

Caris Life Sciences has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortrea$2.72B0.71-$986.20M-$0.73N/A
Caris Life Sciences$348.89M16.81-$68.09M$0.3361.95

Fortrea currently has a consensus target price of $24.23, suggesting a potential upside of 20.47%. Caris Life Sciences has a consensus target price of $31.18, suggesting a potential upside of 52.52%. Given Caris Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Caris Life Sciences is more favorable than Fortrea.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortrea
2 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.46
Caris Life Sciences
1 Sell rating(s)
5 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.50

Fortrea has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market. Comparatively, Caris Life Sciences has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market.

Caris Life Sciences has a net margin of 9.16% compared to Fortrea's net margin of -2.58%. Caris Life Sciences' return on equity of 16.00% beat Fortrea's return on equity.

Company Net Margins Return on Equity Return on Assets
Fortrea-2.58% 13.98% 2.76%
Caris Life Sciences 9.16%16.00%8.05%

In the previous week, Fortrea had 2 more articles in the media than Caris Life Sciences. MarketBeat recorded 10 mentions for Fortrea and 8 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 0.61 beat Fortrea's score of 0.58 indicating that Caris Life Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fortrea
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Caris Life Sciences
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Caris Life Sciences beats Fortrea on 11 of the 15 factors compared between the two stocks.

How does Fortrea compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Fortrea (NASDAQ:FTRE) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

In the previous week, Adaptive Biotechnologies had 4 more articles in the media than Fortrea. MarketBeat recorded 14 mentions for Adaptive Biotechnologies and 10 mentions for Fortrea. Fortrea's average media sentiment score of 0.58 beat Adaptive Biotechnologies' score of 0.36 indicating that Fortrea is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Adaptive Biotechnologies
5 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fortrea
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Adaptive Biotechnologies has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market. Comparatively, Fortrea has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market.

Adaptive Biotechnologies has higher earnings, but lower revenue than Fortrea. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Fortrea, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptive Biotechnologies$276.98M16.51-$59.50M-$0.45N/A
Fortrea$2.72B0.71-$986.20M-$0.73N/A

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 5.7% of Adaptive Biotechnologies shares are owned by insiders. Comparatively, 0.7% of Fortrea shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Adaptive Biotechnologies currently has a consensus target price of $30.31, suggesting a potential upside of 7.30%. Fortrea has a consensus target price of $24.23, suggesting a potential upside of 20.47%. Given Fortrea's higher probable upside, analysts clearly believe Fortrea is more favorable than Adaptive Biotechnologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adaptive Biotechnologies
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Fortrea
2 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.46

Fortrea has a net margin of -2.58% compared to Adaptive Biotechnologies' net margin of -23.67%. Fortrea's return on equity of 13.98% beat Adaptive Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Adaptive Biotechnologies-23.67% -23.95% -8.01%
Fortrea -2.58%13.98%2.76%

Summary

Adaptive Biotechnologies and Fortrea tied by winning 8 of the 16 factors compared between the two stocks.

How does Fortrea compare to Sotera Health?

Fortrea (NASDAQ:FTRE) and Sotera Health (NASDAQ:SHC) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Fortrea presently has a consensus target price of $24.23, suggesting a potential upside of 20.47%. Sotera Health has a consensus target price of $21.14, suggesting a potential upside of 29.81%. Given Sotera Health's stronger consensus rating and higher possible upside, analysts clearly believe Sotera Health is more favorable than Fortrea.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortrea
2 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.46
Sotera Health
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60

91.0% of Sotera Health shares are held by institutional investors. 0.7% of Fortrea shares are held by company insiders. Comparatively, 15.4% of Sotera Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Fortrea has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market. Comparatively, Sotera Health has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market.

Sotera Health has a net margin of 14.11% compared to Fortrea's net margin of -2.58%. Sotera Health's return on equity of 38.46% beat Fortrea's return on equity.

Company Net Margins Return on Equity Return on Assets
Fortrea-2.58% 13.98% 2.76%
Sotera Health 14.11%38.46%7.66%

In the previous week, Fortrea had 8 more articles in the media than Sotera Health. MarketBeat recorded 10 mentions for Fortrea and 2 mentions for Sotera Health. Sotera Health's average media sentiment score of 1.04 beat Fortrea's score of 0.58 indicating that Sotera Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fortrea
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Sotera Health
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Sotera Health has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortrea$2.72B0.71-$986.20M-$0.73N/A
Sotera Health$1.16B4.00$77.94M$0.6027.15

Summary

Sotera Health beats Fortrea on 14 of the 17 factors compared between the two stocks.

Get Fortrea News Delivered to You Automatically

Sign up to receive the latest news and ratings for FTRE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FTRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FTRE vs. The Competition

MetricFortreaLife Sciences Tools & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.89B$10.75B$7.74B$11.62B
Dividend YieldN/A1.45%2.46%4.43%
P/E Ratio-26.8451.1234.1629.83
Price / Sales0.698.348.485.62
Price / Cash2.0226.6921.9322.50
Price / Book3.554.454.373.66
Net Income-$986.20M$57.48B$3.52B$392.18M
7 Day Performance-8.42%-4.85%-5.43%-4.26%
1 Month Performance-12.89%-1.00%-4.54%-6.73%
1 Year Performance100.10%20.94%-1.42%-7.08%

Fortrea Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FTRE
Fortrea
4.189 of 5 stars
$19.59
-1.0%
$24.23
+23.7%
+90.1%$1.89B$2.72BN/A14,300
TWST
Twist Bioscience
2.607 of 5 stars
$132.89
-1.8%
$153.00
+15.1%
+290.9%$8.14B$376.57MN/A979
TXG
10x Genomics
2.8403 of 5 stars
$63.91
-1.8%
$68.40
+7.0%
+246.1%$8.11B$642.82MN/A1,178
CAI
Caris Life Sciences
4.2107 of 5 stars
$25.14
-1.7%
$31.18
+24.0%
N/A$7.17B$348.89M75.781,846
ADPT
Adaptive Biotechnologies
2.1527 of 5 stars
$30.41
+0.5%
$30.31
-0.3%
+97.7%$4.77B$276.98MN/A624

Related Companies and Tools


This page (NASDAQ:FTRE) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners